Prostate Cancer Clinical Trials in Houston

Showing 21-40 of 287 trials

Active Not RecruitingPhase 2< 1 mile

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

NCT05219500

The treatment regimen will consist of 4 doses of FPI-2265

Metastatic Castration Resistant Prostate Cancer

Fusion Pharmaceuticals Inc.115 participantsStarted Dec 2021

Omaha, Nebraska, United States • Houston, Texas, United States

RECRUITINGPhase 1/2< 1 mile

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

NCT06085729

To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.

Prostate Cancer

M.D. Anderson Cancer Center30 participantsStarted Feb 2024

Houston, Texas, United States

RECRUITINGPhase 2< 1 mile

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.

Metastatic Castration-Resistant Prostate Cancer

Kyntra Bio75 participantsStarted Feb 2026

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +12 more locations

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer Trials in Other Cities

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

Other Conditions in Houston